SOURCE: Health Enhancement Products, Inc.

June 14, 2012 09:00 ET

Health Enhancement Products, Inc. Names New Chief Science Officer

BLOOMFIELD HILLS, MI--(Marketwire - Jun 14, 2012) - Arizona-based algae producer Health Enhancement Products (OTCBB: HEPI) has named Scott Freeman, MD to the post of Chief Science Officer as the Company continues to build out its senior management team. Dr. Freeman will help guide the Company through product development initiatives and compliance requirements.

Dr. Freeman's expertise encompasses all therapeutic areas in clinical drug development including oncology, infectious disease, women's health, gastrointestinal, autoimmune, metabolic, and neurological disorders. Dr. Freeman served as Vice President of Clinical Development at Onyx Pharmaceutical (2001-2006) and was head of both clinical development and operations, which executed the clinical trials for renal cell, melanoma, liver, lung, and colorectal cancer. The Phase 1, 2 and 3 trials in kidney and liver cancer were successfully performed and led to NDA approval of Nexavar. Further, Dr. Freeman was a key leader in the regulatory strategy that led to FDA approval of Nexavar for renal cell and liver cancer.

As Clinical Project Director at Schering-Plough Research Institute (1998-2001), his clinical projects included Phase 1, 2 and 3 trials for an anti-estrogen program, a breast cancer treatment, and a P53 gene therapy program. He was Associate Professor at Tulane University (1992-1998) and also served as the Medical Director for the Blood Center. At that time, he also conducted a basic research and clinical research program which focused on gene therapy for cancer and neurological diseases.

Dr. Freeman developed an HSV-TK gene therapy program to treat ovarian cancer, which genetically modified patients' ovarian tumor cells to sensitize the cells to the anti-viral drug ganciclovir. He served as Adjunct Associate Professor at the University of Rochester (1992-1998) and as a clinical investigator on the seminal human gene therapy studies performed at the National Institutes of Health (NIH) in the late 1980's for cancer and metabolic diseases.

Dr. Freeman has authored sixty-four scientific publications. He earned his BA from the University of Colorado in 1978 and received his MD from the University of Nevada in 1983. Dr. Freeman completed an internship and residency at the University of Minnesota in pediatrics and clinical pathology, respectively.

"We're pleased that Dr. Freeman is able to join the senior management team," states Andrew Dahl, HEPI President & CEO. "Finding and recruiting the ideal candidate with the requisite skills, experience and availability is an involved process in its own right. His expertise and experience will hasten the progress being made on several fronts. He's already engaged in a review of current and prior research, and will be directly involved in shaping the R&D work moving forward. Of particular value is Dr. Freeman's intimate knowledge of clinical trials and compliance strategy, as this will also influence food ingredient, supplement and medical food applications, and provide a competitive advantage."

About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB: HEPI) is a health & wellness company engaged in the development of natural products derived from algae cultures for use as dietary supplements and food ingredients. These natural products are extracted from living algae grown in purified water.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.